![IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable](https://oncodaily.com/pub/uploads/2024/06/download-75-1280x717.jpg)
Jun 29, 2024, 15:03
IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable
Thomas Wu, Research physician at Genentech, shared a post by X:
“Our paper just out on Cancer Cell: IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable and more patients without recurrence than that received CCRT.
Thanks all investigators from 15 sites in China. It is impossible without their hard works!”
Patrick Forde, Co-Director of Division of Upper Aerodigestive Malignancies at John Hopkins, added:
“Outstanding work from Dr. Thomas Wu and colleagues, leading the next generation of studies in earlier stage lung cancer! I had the pleasure of being a reviewer for this manuscript, highly recommend!”
Source: Thomas Wu/X and Patrick Forde/X
Jul 1, 2024, 03:08